Multiple sclerosis and related disorders · 2026
Assessment of serum FAM19A5 level in patients with Neuromyelitis Optica spectrum disorder.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
El-Tellawy Hamdy Naguib, Abd-Elhameed Mohammed Ahmed, Elzohne Randa Ahmed, Rageh Tarek Ali, Danial Sarah Khairy, Mahmoud Doaa Mokhtar, Shalaby Nevin Mohieldin
Аннотация
BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) is currently classified as a principal astrocytopathy accompanied by secondary demyelination . The neuroinflammatory protein FAM19A5 is released by reactive astrocytes following CNS injury. However, data on its role in NMOSD are limited.
AIM: This study aimed to evaluate serum levels of FAM19A5 in patients with NMOSD compared to healthy controls .
METHODS: A cross-sectional comparative study was conducted on 50 NMOSD patients and 40 healthy controls at the Neurology Department, Assiut University Hospitals, Egypt,over a two-year period. Serum aquaporin-4 IgG (AQP4-IgG) antibodies were assessed using a cell-based immunofluorescence assay. Serum FAM19A5 levels were measured using the Human TAFA-5 ELISA kit. Clinical and radiological data from studied sample were collected and analyzed.
RESULTS: Serum FAM19A5 levels were significantly elevated in NMOSD patients compared to healthy controls (median 673.95 ng/L vs. 355.25 ng/L, p < 0.001). ROC curve analysis demonstrated that FAM19A5 had good diagnostic performance in distinguishing NMOSD patients from healthy controls, with an area under the curve (AUC) of 0.836, a sensitivity of 64.0%, and a specificity of 97.5% at a cutoff value >600 ng/L.
CONCLUSION: Serum FAM19A5 levels are significantly elevated in patients with NMOSD compared to healthy individuals, suggesting its potential utility as a diagnostic biomarker of NMOSD.
AIM: This study aimed to evaluate serum levels of FAM19A5 in patients with NMOSD compared to healthy controls .
METHODS: A cross-sectional comparative study was conducted on 50 NMOSD patients and 40 healthy controls at the Neurology Department, Assiut University Hospitals, Egypt,over a two-year period. Serum aquaporin-4 IgG (AQP4-IgG) antibodies were assessed using a cell-based immunofluorescence assay. Serum FAM19A5 levels were measured using the Human TAFA-5 ELISA kit. Clinical and radiological data from studied sample were collected and analyzed.
RESULTS: Serum FAM19A5 levels were significantly elevated in NMOSD patients compared to healthy controls (median 673.95 ng/L vs. 355.25 ng/L, p < 0.001). ROC curve analysis demonstrated that FAM19A5 had good diagnostic performance in distinguishing NMOSD patients from healthy controls, with an area under the curve (AUC) of 0.836, a sensitivity of 64.0%, and a specificity of 97.5% at a cutoff value >600 ng/L.
CONCLUSION: Serum FAM19A5 levels are significantly elevated in patients with NMOSD compared to healthy individuals, suggesting its potential utility as a diagnostic biomarker of NMOSD.